May 7, 2013
Boehringer Ingelheim (BI) Japan posted ethical drug sales of 216,398 million yen on an NHI price basis in 2012, up 7.3% from the previous year, driven by a sales increase of its anticoagulant Prazaxa (dabigatran), according to the financial results...read more